Literature DB >> 29805674

Terminally differentiated CD8+ T cells and CD57-FOXP3+CD8+ T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes.

Junji Akagi1, Hideo Baba2, Teruaki Sekine3, Kenji Ogawa4.   

Abstract

Treatment with activated autologous lymphocytes (AALs) has demonstrated mixed results for cancer treatment. Preliminary results revealed that the proportion of cluster of differentiation (CD)8+CD57+ T cells is significantly increased in AALs, indicating that they are able to determine treatment outcome. Therefore, the role of CD8+CD57+ T cells in AAL efficacy was investigated. T lymphocytes were isolated from 35 patients with stage IV gastric carcinomas (17 men and 18 women; aged 41-84 years) receiving immunotherapy using AALs (IAAL). Using fluorescence activated cell sorting, CD8, CD27, CD57, and forkhead box protein 3 (FOXP3) expression was investigated on CD8+ T cell populations in CD8+ T cell differentiation prior to and following in vitro culture. The association between these populations and progression-free survival (PFS) was analyzed using Cox univariate, and multivariate analyses and Kaplan-Meier survival analysis. CD57 expression was negative in early-differentiated CD8+ T cells (CD27+CD8+CD57-), and positive in intermediate- (CD27+CD8+CD57+) and terminal- (CD27-CD8+CD57+) differentiated CD8+ T cells. Univariate analysis revealed a significant association between terminal-CD8+ T cells and longer PFS times (P=0.035), whereas CD57-FOXP3+CD8+ T cells were associated with shorter PFS times. Multivariate analysis revealed that CD57-FOXP3+CD8+ T cells was an independent poor prognostic factor, whereas CD57+FOXP3+CD8+ T cells were not associated with PFS. Although IAAL increased the proportion of terminal-CD8+ T cells relative to the pre-culture proportions, patients with a high CD57-FOXP3+CD8+ T cell percentage exhibited repressed terminal-CD8+ T cell induction, leading to poor patient prognosis. Terminally differentiated CD27-CD8+CD57+ T cells were responsible for the effectiveness of AALs; however, CD57-FOXP3+CD8+ T cells abrogated their efficacy, possibly by inhibiting their induction.

Entities:  

Keywords:  T cell differentiation; activated autologous lymphocytes; cluster of differentiation 57; forkhead box protein 3; gastric cancer; immunotherapy

Year:  2018        PMID: 29805674      PMCID: PMC5958768          DOI: 10.3892/ol.2018.8512

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

1.  Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

Authors:  Li-Zhen He; Naseem Prostak; Lawrence J Thomas; Laura Vitale; Jeffrey Weidlick; Andrea Crocker; Catherine D Pilsmaker; Sarah M Round; Alison Tutt; Martin J Glennie; Henry Marsh; Tibor Keler
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

Review 2.  CD27 and CD70 in T cell and B cell activation.

Authors:  Jannie Borst; Jenny Hendriks; Yanling Xiao
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

3.  Parallel expansion of human virus-specific FoxP3- effector memory and de novo-generated FoxP3+ regulatory CD8+ T cells upon antigen recognition in vitro.

Authors:  Eva Billerbeck; Hubert E Blum; Robert Thimme
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

4.  The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age.

Authors:  Rita Simone; Anna Zicca; Daniele Saverino
Journal:  J Leukoc Biol       Date:  2008-09-09       Impact factor: 4.962

5.  Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Authors:  Andrea Anichini; Alessandra Molla; Claudia Vegetti; Ilaria Bersani; Roberta Zappasodi; Flavio Arienti; Fernando Ravagnani; Andrea Maurichi; Roberto Patuzzo; Mario Santinami; Hanspeter Pircher; Massimo Di Nicola; Roberta Mortarini
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

6.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.

Authors:  Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

7.  Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer.

Authors:  Junji Akagi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 8.  Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.

Authors:  Martijn A Nolte; Ronald W van Olffen; Klaas P J M van Gisbergen; René A W van Lier
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 9.  Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation?

Authors:  Vinodh Pillai; Nitin J Karandikar
Journal:  Immunol Lett       Date:  2007-09-29       Impact factor: 3.685

10.  New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Authors:  Richard C Wu; Patrick Hwu; Laszlo G Radvanyi
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

View more
  1 in total

1.  Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients.

Authors:  Alhasan Alsalman; Mohammad A Al-Mterin; Khaled Murshed; Ferial Alloush; Samia T Al-Shouli; Salman M Toor; Eyad Elkord
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.